Boston Family Office Increased Position in Abbott Laboratories (ABT); Johnson & Johnson (JNJ) Holder Ancora Advisors Has Lifted Stake

Johnson & Johnson (NYSE:JNJ) Logo

Boston Family Office Llc increased its stake in Abbott Laboratories (ABT) by 5.22% based on its latest 2018Q3 regulatory filing with the SEC. Boston Family Office Llc bought 5,529 shares as the company’s stock rose 6.57% while stock markets declined. The institutional investor held 111,362 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $8.17M, up from 105,833 at the end of the previous reported quarter. Boston Family Office Llc who had been investing in Abbott Laboratories for a number of months, seems to be bullish on the $130.64B market cap company. The stock decreased 0.91% or $0.68 during the last trading session, reaching $74.38. About 5.70M shares traded. Abbott Laboratories (NYSE:ABT) has risen 29.68% since February 14, 2018 and is uptrending. It has outperformed by 29.68% the S&P500. Some Historical ABT News: 23/05/2018 – ABBOTT GETS FDA OK FOR XIENCE SIERRA HEART STENT; 18/04/2018 – Abbott Labs, Morgan Stanley, U.S. Bancorp, American Express, Alcoa and Pier 1 Imports are all scheduled to publish their latest earnings updates; 31/05/2018 – Abbott Introduces the Afinion 2 Analyzer Rapid Test System for Diabetes Management; 23/05/2018 – Abbott Labs: Tendyne Shows Significant Reduction of Mitral Regurgitation Symptoms and Low Mortality Rates; 23/05/2018 – Abbott’s Investigational Tendyne™ Device for Mitral Valve Replacement Demonstrates Positive Outcomes at 30 Days in Global Stu; 22/05/2018 – FDA: ABBOTT RECALLS HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM; 11/04/2018 – Abbott Initiates Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease; 18/05/2018 – Texas Gov. Abbott: Suspected Shooter Has No Criminal History; 29/03/2018 – ABBOTT INITIATES GUIDE-HF CLINICAL TRIAL USING CARDIOMEMS; 18/04/2018 – Abbott Labs 1Q EPS 23c

Ancora Advisors Llc increased its stake in Johnson & Johnson (JNJ) by 22.54% based on its latest 2018Q3 regulatory filing with the SEC. Ancora Advisors Llc bought 30,418 shares as the company’s stock rose 5.87% while stock markets declined. The hedge fund held 165,346 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $22.85 million, up from 134,928 at the end of the previous reported quarter. Ancora Advisors Llc who had been investing in Johnson & Johnson for a number of months, seems to be bullish on the $360.59B market cap company. The stock increased 0.22% or $0.29 during the last trading session, reaching $134.45. About 7.90 million shares traded. Johnson & Johnson (NYSE:JNJ) has risen 3.75% since February 14, 2018 and is uptrending. It has outperformed by 3.75% the S&P500. Some Historical JNJ News: 29/05/2018 – Novo Nordisk’s oral diabetes drug beats Jardiance in study; 20/03/2018 – Johnson & Johnson to Host Investor Conference Call on First-Quarter Results; 17/04/2018 – Johnson & Johnson 1Q Adj EPS $2.06; 04/04/2018 – J&J Jury Set to Weigh Banker’s Claims Baby Powder Caused Cancer; 12/03/2018 – MEDIA-India’s Macleods Pharma in talks with J&J for licence deal of tuberculosis drug – Economic Times; 16/03/2018 – J&J – TRANSACTION WAS CONTEMPLATED IN COMPANY’S GUIDANCE PROVIDED ON JANUARY 23, 2018; 14/03/2018 – South Dakota sues opioid makers as litigation swells; 27/03/2018 – FDA: Johnson & Johnson Vision Care, Inc.- 1-DAY ACUVUE Moist for ASTIGMATISM Brand Contact Lenses; 11/04/2018 – JOHNSON & JOHNSON JNJ.N , IMERYS SA IMTP.PA SUBSIDIARY ORDERED TO PAY $80 MLN IN PUNITIVE DAMAGES IN NEW JERSEY CASE BLAMING TALC FOR MESOTHELIOMA -COURTROOM VIDEO; 07/05/2018 – REG-Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Newly Diagnosed Multiple Myeloma

Investors sentiment increased to 1.05 in Q3 2018. Its up 0.08, from 0.97 in 2018Q2. It improved, as 43 investors sold JNJ shares while 748 reduced holdings. 115 funds opened positions while 719 raised stakes. 1.70 billion shares or 7.91% less from 1.84 billion shares in 2018Q2 were reported. Pggm Invests has invested 1.26% in Johnson & Johnson (NYSE:JNJ). Mawer Investment Management Limited invested in 1.52M shares or 1.58% of the stock. Clarivest Asset Mngmt Ltd Com stated it has 0.72% in Johnson & Johnson (NYSE:JNJ). New York-based South Street Advisors Lc has invested 0.2% in Johnson & Johnson (NYSE:JNJ). Gemmer Asset Mngmt Limited Liability Company reported 0.51% stake. Fred Alger reported 35,101 shares. Mcmillion Mgmt Incorporated reported 2.53% stake. Reik And Limited Liability owns 0.69% invested in Johnson & Johnson (NYSE:JNJ) for 17,347 shares. Texas Permanent School Fund holds 602,247 shares. Payden And Rygel stated it has 10,200 shares. 24.98 million were accumulated by . Argent Trust stated it has 124,188 shares. Chesapeake Asset Mgmt has invested 0.36% in Johnson & Johnson (NYSE:JNJ). Cedar Hill Limited has invested 0.16% in Johnson & Johnson (NYSE:JNJ). Georgia-based Montag Caldwell Ltd has invested 0.01% in Johnson & Johnson (NYSE:JNJ).

Among 25 analysts covering Johnson & Johnson (NYSE:JNJ), 12 have Buy rating, 4 Sell and 9 Hold. Therefore 48% are positive. Johnson & Johnson had 111 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Johnson & Johnson (NYSE:JNJ) earned “Hold” rating by Jefferies on Tuesday, August 15. The rating was maintained by Credit Suisse on Wednesday, October 17 with “Outperform”. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by Jefferies on Wednesday, October 18. The firm has “Sell” rating given on Friday, May 20 by Standpoint Research. As per Tuesday, August 25, the company rating was maintained by Cowen & Co. The stock has “Overweight” rating by JP Morgan on Monday, May 15. On Thursday, July 12 the stock rating was upgraded by Goldman Sachs to “Neutral”. UBS maintained Johnson & Johnson (NYSE:JNJ) on Thursday, August 31 with “Buy” rating. Morgan Stanley maintained Johnson & Johnson (NYSE:JNJ) rating on Thursday, October 11. Morgan Stanley has “Equal-Weight” rating and $153 target. The rating was downgraded by Alembic on Friday, July 21 to “Underweight”.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Seekingalpha.com which released: “JNJ up 1% premarket on strong Q4 – Seeking Alpha” on January 22, 2019, also Seekingalpha.com with their article: “Covered-Call Writing With J&J – Seeking Alpha” published on January 24, 2019, Streetinsider.com published: “Missouri Supreme Court Strikes Blow to Litigation Tourism, J&J (JNJ) Wins Court’s Block on Defect Trials, Court Limits Bundling of Out-of-State Plaintiffs – Bloomberg – StreetInsider.com” on February 13, 2019. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Investorplace.com and their article: “5 Top Stock Trades for Wednesday: JNJ, CMG, MO, EBAY – Investorplace.com” published on January 22, 2019 as well as Seekingalpha.com‘s news article titled: “JNJ’s TECNIS Eyhance IOL available in Europe – Seeking Alpha” with publication date: February 04, 2019.

Ancora Advisors Llc, which manages about $3.12B and $2.60 billion US Long portfolio, decreased its stake in Intel Corp (NASDAQ:INTC) by 38,209 shares to 228,820 shares, valued at $10.82M in 2018Q3, according to the filing. It also reduced its holding in Ishares Tr (IWM) by 7,673 shares in the quarter, leaving it with 28,966 shares, and cut its stake in Voya Finl Inc (NYSE:VOYA).

Since August 27, 2018, it had 3 insider purchases, and 8 selling transactions for $79.44 million activity. Sneed Michael E had sold 29,000 shares worth $3.91M. Kapusta Ronald A sold $1.08 million worth of stock or 7,899 shares. Fasolo Peter sold $24.41 million worth of stock. 40,000 Johnson & Johnson (NYSE:JNJ) shares with value of $5.77M were sold by Duato Joaquin. Gorsky Alex also sold $38.60M worth of Johnson & Johnson (NYSE:JNJ) shares. MULCAHY ANNE M had bought 748 shares worth $100,050.

Boston Family Office Llc, which manages about $1.02B and $948.96 million US Long portfolio, decreased its stake in Kinder Morgan (NYSE:KMI) by 92,405 shares to 196,348 shares, valued at $3.48M in 2018Q3, according to the filing. It also reduced its holding in General Electric Co (NYSE:GE) by 59,789 shares in the quarter, leaving it with 160,064 shares, and cut its stake in Procter & Gamble (NYSE:PG).

Since August 29, 2018, it had 1 insider buy, and 10 sales for $36.98 million activity. LANE ANDREW H sold $610,513 worth of Abbott Laboratories (NYSE:ABT) on Wednesday, August 29. $4.62M worth of Abbott Laboratories (NYSE:ABT) was sold by Watkin Jared. 142,341 Abbott Laboratories (NYSE:ABT) shares with value of $10.30M were sold by WHITE MILES D. 58,200 shares valued at $4.00 million were sold by Blaser Brian J on Thursday, September 20. Bracken Sharon J also sold $127,044 worth of Abbott Laboratories (NYSE:ABT) on Friday, September 28. Shares for $366,957 were sold by Salvadori Daniel Gesua Sive on Friday, September 28.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare – Seeking Alpha” on October 16, 2018, also Seekingalpha.com with their article: “How Safe Is Abbott Laboratories’ Dividend? – Seeking Alpha” published on January 17, 2019, Seekingalpha.com published: “Abbott collaborates with Malaria No More – Seeking Alpha” on January 11, 2019. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Benzinga.com and their article: “Earnings Scheduled For January 23, 2019 – Benzinga” published on January 23, 2019 as well as Benzinga.com‘s news article titled: “Sell-Side Issues Positive Prognosis For Abbott (NYSE:ABT) Following Mixed Q4 Results, Strong 2019 Outlook – Benzinga” with publication date: January 24, 2019.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart